Dexamethasone in the Treatment of COVID-19: Primus Inter Pares?

被引:13
作者
Romanou, Vasiliki [1 ,2 ]
Koukaki, Evangelia [1 ,2 ]
Chantziara, Vasiliki [1 ,2 ]
Stamou, Panagiota [1 ,2 ]
Kote, Alexandra [1 ,2 ]
Vasileiadis, Ioannis [1 ,2 ]
Koutsoukou, Antonia [1 ,2 ]
Rovina, Nikoletta [1 ]
机构
[1] Natl & Kapodistrian Univ Athens, Med Sch, Dept Resp Med 1, Athens 11527, Greece
[2] Sotiria Chest Dis Hosp, Athens 11527, Greece
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 06期
关键词
dexamethasone; corticosteroids; COVID-19; RESPIRATORY-DISTRESS-SYNDROME; CORTICOSTEROID-THERAPY; TERM USE; DISEASE; GLUCOCORTICOIDS; MULTICENTER; INFECTION; METAANALYSIS; PNEUMONIA; COHORT;
D O I
10.3390/jpm11060556
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread globally, becoming a huge public health challenge. Even though the vast majority of patients are asymptomatic, some patients present with pneumonia, acute respiratory distress syndrome (ARDS), septic shock, and death. It has been shown in several studies that the severity and clinical outcomes are related to dysregulated antiviral immunity and enhanced and persistent systemic inflammation. Corticosteroids have been used for the treatment of COVID-19 patients, as they are reported to elicit benefits by reducing lung inflammation and inflammation-induced lung injury. Dexamethasone has gained a major role in the therapeutic algorithm of patients with COVID-19 pneumonia requiring supplemental oxygen or on mechanical ventilation. Its wide anti-inflammatory action seems to form the basis for its beneficial action, taming the overwhelming "cytokine storm". Amid a plethora of scientific research on therapeutic options for COVID-19, there are still unanswered questions about the right timing, right dosing, and right duration of the corticosteroid treatment. The aim of this review article was to summarize the data on the dexamethasone treatment in COVID-19 and outline the clinical considerations of corticosteroid therapy in these patients.
引用
收藏
页数:25
相关论文
共 89 条
[1]   The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis [J].
Ahmadikia, Kazem ;
Hashemi, Seyed Jamal ;
Khodavaisy, Sadegh ;
Getso, Muhammad Ibrahim ;
Alijani, Neda ;
Badali, Hamid ;
Mirhendi, Hossein ;
Salehi, Mohammadreza ;
Tabari, Azin ;
Mohammadi Ardehali, Mojtaba ;
Kord, Mohammad ;
Roilides, Emmanuel ;
Rezaie, Sassan .
MYCOSES, 2021, 64 (08) :798-808
[2]   Corticosteroid treatment has no effect on hospital mortality in COVID-19 patients [J].
Albani, Filippo ;
Fusina, Federica ;
Granato, Enza ;
Capotosto, Cristina ;
Ceracchi, Claudia ;
Gargaruti, Riccardo ;
Santangelo, Giovanni ;
Schiavone, Luca ;
Taranto, Maria Salvatrice ;
Tosati, Cinzia ;
Vavassori, Elena ;
Natalini, Giuseppe .
SCIENTIFIC REPORTS, 2021, 11 (01)
[3]   Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial [J].
Angus, Derek C. ;
Derde, Lennie ;
Al-Beidh, Farah ;
Annane, Djillali ;
Arabi, Yaseen ;
Beane, Abigail ;
Van Bentum-Puijk, Wilma ;
Berry, Lindsay ;
Bhimani, Zahra ;
Bonten, Marc ;
Bradbury, Charlotte ;
Brunkhorst, Frank ;
Buxton, Meredith ;
Buzgau, Adrian ;
Cheng, Allen C. ;
de Jong, Menno ;
Detry, Michelle ;
Estcourt, Lise ;
Fitzgerald, Mark ;
Goossens, Herman ;
Green, Cameron ;
Haniffa, Rashan ;
Higgins, Alisa M. ;
Horvat, Christopher ;
Hullegie, Sebastiaan J. ;
Kruger, Peter ;
Lamontagne, Francois ;
Lawler, Patrick R. ;
Linstrum, Kelsey ;
Litton, Edward ;
Lorenzi, Elizabeth ;
Marshall, John ;
McAuley, Daniel ;
McGlothin, Anna ;
McGuinness, Shay ;
McVerry, Bryan ;
Montgomery, Stephanie ;
Mouncey, Paul ;
Murthy, Srinivas ;
Nichol, Alistair ;
Parke, Rachael ;
Parker, Jane ;
Rowan, Kathryn ;
Sanil, Ashish ;
Santos, Marlene ;
Saunders, Christina ;
Seymour, Christopher ;
Turner, Anne ;
van de Veerdonk, Frank ;
Venkatesh, Balasubramanian .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (13) :1317-1329
[4]  
[Anonymous], 2020, Global Strategy for Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2020 report
[5]  
[Anonymous], 2020, INTENS CARE MED, DOI DOI 10.1007/s00134-020-06022-5
[6]   Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis [J].
Armstrong-James, Darius ;
Youngs, Jonathan ;
Bicanic, Tihana ;
Abdolrasouli, Alireza ;
Denning, David W. ;
Johnson, Elizabeth ;
Mehra, Varun ;
Pagliuca, Tony ;
Patel, Brijesh ;
Rhodes, Johanna ;
Schelenz, Silke ;
Shah, Anand ;
van de Veerdonk, Frank L. ;
Verweij, Paul E. ;
White, P. Lewis ;
Fisher, Matthew C. .
EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (04)
[7]   COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network [J].
Buetti, Niccolo ;
Ruckly, Stephane ;
de Montmollin, Etienne ;
Reignier, Jean ;
Terzi, Nicolas ;
Cohen, Yves ;
Shiami, Shidasp ;
Dupuis, Claire ;
Timsit, Jean-Francois .
INTENSIVE CARE MEDICINE, 2021, 47 (02) :180-187
[8]   Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes Systematic Review and Meta-analysis [J].
Cano, Edison J. ;
Fuentes, Xavier Fonseca ;
Campioli, Cristina Corsini ;
O'Horo, John C. ;
Abu Saleh, Omar ;
Odeyemi, Yewande ;
Yadav, Hemang ;
Temesgen, Zelalem .
CHEST, 2021, 159 (03) :1019-1040
[9]   Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD [J].
Cantoli, Marco ;
Pauletti, Alessia ;
Rossi, Maria Rita ;
Spanevello, Antonio ;
Casolari, Paolo ;
Marcellini, Andrea ;
Forini, Giacomo ;
Gnesini, Giulia ;
Marku, Brunilda ;
Barnes, Neil ;
Rizzi, Andrea ;
Curradi, Giacomo ;
Caramori, Gaetano ;
Morelli, Paolo ;
Papi, Alberto .
EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (04)
[10]   Effects of representative glucocorticoids on TNFα- and CD40L-induced NF-κB activation in sensor cells [J].
Cechin, Sirlene R. ;
Buchwald, Peter .
STEROIDS, 2014, 85 :36-43